ArticleCureus2024
Diagnostic Accuracy of Spectral Doppler Indices and Sonoelastography in Predicting Malignancy in Breast Imaging Reporting and Database System 3 Breast Lesions With Histopathology as the Reference Standard.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Breast cancer is a significant health concern in India, representing a large portion of all cancers affecting women and ranking as one of the most common cancers overall. Reliable diagnostic tools are essential for accurately predicting malignancy and reducing the need for unnecessary biopsies. A Breast Imaging Reporting and Database System (BI-RADS) 3 designation suggests a low likelihood of cancer, indicating that findings are likely benign. For these cases, short-term follow-up imaging is generally preferred over immediate biopsy as the probability of malignancy is minimal. This study evaluates the effectiveness of strain elastography, specifically the strain ratio, in predicting malignancy in BI-RADS 3 breast lesions in a cohort of 50 patients. Additionally, it examines the role of Doppler indices, including the Pulsatility Index (PI) and Resistance Index (RI). Histopathological analysis was used as the reference standard. Methods A descriptive cross-sectional study was conducted on 50 patients presenting with palpable breast lumps or abnormalities detected via ultrasonography or mammography. Conventional B-mode ultrasound examinations were performed on all the patients, and those with BI-RADS 3 lesions were identified. The Doppler technique was employed to calculate PI and RI values, followed by strain elastography to determine the strain ratio. Histopathological confirmation was performed for all patients. Results Histopathological analysis revealed that 92% (N=46) of the lesions were benign, while 8% (N=4) were malignant. For strain elastography, the sensitivity was 75%, specificity was 97.83%, positive predictive value (PPV) was 75%, negative predictive value (NPV) was 97.83%, and the diagnostic accuracy was 96%. For Doppler PI, the sensitivity was 75%, specificity was 95.65%, PPV was 60%, NPV was 97.78%, and the overall diagnostic accuracy was 94%. Similarly, for Doppler RI, the sensitivity was 75%, specificity was 95.65%, PPV was 60%, NPV was 97.78%, and the overall diagnostic accuracy was 94%. Conclusion B-mode ultrasound remains the first-line imaging investigation for evaluating breast masses. In BI-RADS 3 lesions, where the likelihood of malignancy is minimal, the combined use of strain elastography and Doppler PI and RI indices can serve as a valuable adjunct in predicting malignancy and reducing the need for unnecessary biopsies. Moreover, strain elastography demonstrates higher diagnostic accuracy compared to Doppler PI and RI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.